US Pharma MarketingThe post EyePoint halves workforce and ends Phase III trial early after endpoint miss appeared first on Clinical Trials Arena.
EyePoint halves workforce and ends Phase III trial early after endpoint miss
The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year. The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year. EyePoint will now look to develop duravyu in DME. Credit: ozrimoz / Shutterstock.com. EyePoint Pharmaceuticals has announced sweeping job cuts after its eye disease candidate, duravyu, failed to meet its key goal during a late-stage study in wet age-related macular degeneration (wAMD). This miss stems from the Phase III LUCIA study (NCT06683742), in which EyePoint pitted duravyu against Bayer and…
The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year.
Source: Clinical Trials Arena